Isabel Saraiva BREAKING
NEWS Why Mobilise-D matters – now more than ever! LATEST
VIDEO More Videos npj Digital Medicine Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes Polhemus et al. & Mobilise-D Other publications LATEST
PUBLICATION SOCIAL MEDIA Public Newsletter Jan-Aug 2021 BREAKING
NEWS Why Mobilise-D matters – now more than ever! LATEST
VIDEO More Videos npj Digital Medicine Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes Polhemus et al. & Mobilise-D Other publications LATEST
PUBLICATION SOCIAL MEDIA Tova Gur Arieh BREAKING
NEWS Why Mobilise-D matters – now more than ever! LATEST
VIDEO More Videos npj Digital Medicine Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes Polhemus et al. & Mobilise-D Other publications LATEST
PUBLICATION SOCIAL MEDIA EMA Public Support for Mobilise-D: Follow-up BREAKING
NEWS Why Mobilise-D matters – now more than ever! LATEST
VIDEO More Videos npj Digital Medicine Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes Polhemus et al. & Mobilise-D Other publications LATEST
PUBLICATION SOCIAL MEDIA When life gives you lemons, make Lemon Drizzle cake! BREAKING
NEWS Why Mobilise-D matters – now more than ever! LATEST
VIDEO More Videos npj Digital Medicine Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes Polhemus et al. & Mobilise-D Other publications LATEST
PUBLICATION SOCIAL MEDIA Mobilise-D and IDEA-FAST announce the creation of the Digital Health Catalyst (DHC) BREAKING
NEWS Why Mobilise-D matters – now more than ever! LATEST
VIDEO More Videos npj Digital Medicine Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes Polhemus et al. & Mobilise-D Other publications LATEST
PUBLICATION SOCIAL MEDIA

Connecting digital mobility assessment to clinical outcomes
for regulatory and clinical endorsement

What?

What?

Mobilise-D is a 5-year, IMI-funded project that will produce validated and accepted digital mobility outcomes to monitor daily life gait of people with different mobility problems, with the goal to improve follow-up and personalized care.

About Us

How?

How?

Mobilise-D will perform a technical and clinical validation of a sensor-algorithm pair in different patient groups. We maintain close dialogue with the European Medicines Agency (EMA) to facilitate the process of regulatory approval.

About Us

Who?

Who?

The Mobilise-D consortium consists of 34 partners from Europe and the USA. Over 200 professionals with technical, clinical, and regulatory expertise will work together to bring digital mobility outcomes to the clinic.                                                                  

About Us

Mobility – how well we walk – is an important marker of health; a slow walking speed is associated with greater mortality, morbidity, cognitive decline, dementia, and fall risk. As the population ages, the number of people experiencing mobility challenges is expected to rise. However, accurately assessing people’s mobility, especially in the real daily life world, is far from easy.

Mobilise-D will develop a comprehensive system to monitor and evaluate people’s gait based on digital technologies, including sensors worn on the body. The project focuses on conditions which often affect mobility, namely chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure.

The Mobilise-D results will help to improve the accurate assessment of daily life mobility in clinical trials and patient treatment, thereby contributing to improved and more personalised care.

Patient Groups

Mobilise-D will focus on five different patient groups that together represent respiratory problems (chronic obstructive pulmonary disease – COPD), neurodegenerative conditions (Parkinson’s disease – PD), neuroinflammatory problems (multiple sclerosis – MS), osteoporosis and sarcopenia (hip fracture recovery/proximal femoral fracture – PFF), and cardiac pathology (congestive heart failure – CHF).

These patient groups cover a range of walking speed, mobility challenges, and potential events that we care about, such as improving versus worsening of function, falls, hospitalisation, nursing home admission, and death. Furthermore, these patient groups will be followed at 12 different sites across Europe, ensuring a good geographical representation and covering a diverse representation of health care organisation, such as in- versus outpatient care, as well as public versus private health services.

Read More

Twitter Feed

Mobilise-D @Mobilise_D

Clemens Becker represents #MobiliseD during a panel discussion today (15:40 UTC+1) at the #Digital #Biomarker #Summit in #Boston:

"Holistic Measurements- Is The Patient Just the Sum of Their Diseases?"

#digitalhealth #patientcare @IMI_JU @EFPIA https://t.co/LcvpYgYUKs
View on Twitter
Mobilise_D photo
4
12
Mobilise-D @Mobilise_D

Our Mobiliser @AliKeogh88! Read the interview below🤩👇 https://t.co/EAt4PH0cLj
View on Twitter
3
6

Latest News

A new Mobilise-D scoping review: The clinical utility of digital mobility outcomes

Walking has the potential to be a rich indicator of health in many medical conditions. In recent years, scientific research has proposed more than 100 digital mobility outcomes (DMOs) that could be used to assess walking, and thereby monitor health status, using digital technologies. Though they show great promise, these DMOs require further validation.  Researchers must…

Read more

Upcoming Events

No event found!
Sign up for our Newsletter!